Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to define the time a molecule in the participants bones
called NTX begins to rise after receiving treatment with bisphosphonates. NTX is measured in
the urine to determine the rate of bone breakdown. Tracking this marker may help identify a
more optimal dosing schedule of bisphosphonate therapy. Bisphosphonate drugs like zoledronic
acid, which will be used in this study, are used to reduce pain and bone fractures in people
with multiple myeloma. There is some laboratory data to suggest that they may work against
myeloma. Participants will have already undergone bisphosphonate therapy and may have
received zoledronic acid as treatment. Typically these agents are continued indefinitely. Due
to concerns of their long-term side effects we are looking at alternate strategies for
reducing the frequency of these agents.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
American Society of Clinical Oncology Brigham and Women's Hospital Dana-Farber Cancer Institute